Drug induced liver injury: Can biomarkers assist RUCAM in causality assessment?

International Journal of Molecular Sciences

Volumn 18, Issue 4, 2017, Pages

  Teschke, Rolf ^a,b   Schulze, Johannes ^b   Eickhoff, Axel ^a,b   Danan, Gaby ^c  

^a Klinikum Hanau   (Germany)

^b GOETHE UNIVERSITY   (Germany)

^c Pharmacovigilance Consultancy   (France)

Author keywords

Diagnostic biomarkers; DILI; Drug induced liver injury; Pathogenesis; Roussel Uclaf Causality Assessment Method; RUCAM

Indexed keywords

ALANINE AMINOTRANSFERASE; ALKALINE PHOSPHATASE; AMPHETAMINE; ASPARTATE AMINOTRANSFERASE; BILIRUBIN; BIOLOGICAL MARKER; COLONY STIMULATING FACTOR RECEPTOR; CYTOKERATIN 18; GLUTAMATE DEHYDROGENASE; HIGH MOBILITY GROUP B1 PROTEIN; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; IDITOL DEHYDROGENASE; ISONIAZID; MICRORNA 122; MICRORNA 192; OSTEOPONTIN; PARACETAMOL; PYRROLIZIDINE ALKALOID; TACRINE; XENOBIOTIC AGENT;

CAUSALITY; CLINICAL FEATURE; CLINICAL OUTCOME; CLINICAL TRIAL (TOPIC); DIAGNOSTIC PROCEDURE; DRUG SAFETY; HUMAN; IATROGENIC DISEASE; INCIDENCE; NONHUMAN; PATHOGENESIS; PREVALENCE; PROGNOSIS; PUBLICATION; REVIEW; ROUSSEL UCLAF CAUSALITY ASSESSMENT METHOD; SCIENTIFIC LITERATURE; SENSITIVITY AND SPECIFICITY; TOXIC HEPATITIS; ANIMAL; CHEMICAL AND DRUG INDUCED LIVER INJURY; CLASSIFICATION; DRUG EFFECTS; LIVER; METABOLISM; PATHOLOGY; PROCEDURES; REPRODUCIBILITY; RISK ASSESSMENT; RISK FACTOR;

ANIMALS; BIOMARKERS; CHEMICAL AND DRUG INDUCED LIVER INJURY; HUMANS; LIVER; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT; RISK FACTORS; SENSITIVITY AND SPECIFICITY; XENOBIOTICS;

EID: 85017457154     PISSN: 16616596     EISSN: 14220067     Source Type: Journal    
DOI: 10.3390/ijms18040803     Document Type: Review

References (70)

1. Danan, G.; Bénichou, C. Causality assessment of adverse reactions to drugs-I. A novel method based on the conclusions of international consensus meetings: Application to drug-induced liver injuries. J. Clin. Epidemiol. 1993, 46, 1323-1330.
2. Bénichou, C.; Danan, G.; Flahault, A. Causality assessment of adverse reactions to drugs—II. An original model for validation of drug causality assessment methods: Case reports with positive rechallenge. J. Clin. Epidemiol. 1993, 46, 1331-1336.
3. Danan, G.; Teschke, R. RUCAM in drug and herb induced liver injury: The update. Int. J. Mol. Sci. 2016, 17, 14.
4. Zhu, Y.; Niu, M.; Chen, J.; Zou, Z.S.; Ma, Z.J.; Liu, S.H.; Wang, R.L.; He, T.T.; Song, H.B.; Wang, Z.X.; et al. Comparison between Chinese herbal medicine and Western medicine-induced liver injury of 1985 patients. J. Gastroenterol. Hepatol. 2016, 31, 1476-1482.
5. Lu, R.J.; Zhang, Y.; Tang, F.L.; Zheng, Z.W.; Fan, Z.D.; Zhu, S.M.; Qian, X.F.; Liu, N.N. Clinical characteristics of drug-induced liver injury and related risk factors. Exp. Ther. Med. 2016, 12, 2606-2616.
6. Björnsson, E.S. Hepatotoxicity by drugs: The most common implicated agents. Int. J. Mol. Sci. 2016, 17, 224.
7. Sarges, P.; Steinberg, J.M.; Lewis, J.H. Drug-induced liver injury: Highlights from a review of the 2015 literature. Drug Saf. 2016, 39, 561-575.
8. Teschke, R.; Frenzel, C.; Wolff, A.; Eickhoff, A.; Schulze, J. Drug induced liver injury: Accuracy of diagnosis in published reports. Ann. Hepatol. 2014, 13, 248-255.
9. Teschke, R.; Aithal, P.; Danan, G. Drug induced liver injury: Alternative causes as variables confounding causality. Exp. Opin. Drug Saf. 2017, in press.
10. Teschke, R.; Danan, G. Causality assessment methods in drug-induced liver injury. In Drug-induced Liver Toxicity, Editors: Minjun Chen and Yvonne Will; Series: Methods in Pharmacology and Toxicology/Y; Kang, J., Casey, D.C., Eds.; Springer Protocols: Berlin, Germany, 2018; in press.
11. Teschke, R.; Eickhoff, A. Suspected liver injury and the dilemma of causality. Dig. Dis. Sci. 2017, 62, 1095-1098.
12. Wang, F.S.; Fan, J.G.; Zhang, Z.; Gao, B.; Wang, H.Y. The global burden of liver disease: The major impact in China. Hepatology 2014, 60, 2099-2108.
13. Younossi, Z.M.; Stepanova, M.; Affendy, M.; Fang, Y.; Younossi, Y.; Mir, H.; Srishord, M. Changes in the prevalence of the most common causes of chronic liver diseases in the United States from 1988 to 2008. Clin. Gastroenterol. Hepatol. 2011, 9, 524-530.
14. Scaglione, S.; Kliethermes, S.; Cao, G.; Shoham, D.; Durazo, R.; Luke, A.; Volk, M.L. The epidemiology of cirrhosis in the United States: A population-based study. J. Clin. Gastroenterol. 2015, 49, 690-696.
15. Bell, L.N.; Chalasani, N. Epidemiology of idiosyncratic drug-induced liver injury. Semin. Liver Dis. 2009, 29, 337-347.
16. Sgro, C.; Clinard, F.; Ouazir, K.; Chanay, H.; Allard, C.; Guilleminet, C.; Lenoir, C.; Lemoine, A.; Hillon, P. Incidence of drug-induced hepatic injuries: A French population-based study. Hepatology 2002, 36, 451-455.
17. De Valle, M.B.; Av Klinteberg, V.; Alem, N.; Olsson, R.; Björnsson, E. Drug-induced liver injury in a Swedish University hospital out-patient hepatology clinic. Aliment. Pharmacol. Ther. 2006, 24, 1187-1195.
18. Björnsson, E.S.; Bergmann, O.M.; Björnsson, H.K.; Kvaran, R.B.; Olafsson, S. Incidence, presentation and outcomes in patients with drug-induced liver injury in the general population of Iceland. Gastroenterology 2013, 144, 1419-1425.
19. SAFETY-T Consortium: DILI BM Summary Data Package. Release date 30 September 2016. Available online: http://www.imi-safe-t.eu/htdocs/biomarker/drug-induced-injury/activities.html (accessed on 21 February 2017)
20. EMA. Letter of Support for Drug-Induced Liver Injury (DILI) Biomarker. EMA/423870/2016, Edited G. Rassi. Last Updated: 30 September 2016. Available online: http://www.ema.europa.eu/docs/en_GB/document_library/Other/2016/09/WC500213479.pdf (accessed on 15 February 2017).
21. Fontana, R.J. Pathogenesis of idiosyncratic drug-induced liver injury and clinical perspectives. Gastroenterology 2014, 146, 914-928.
22. Shi, Q.; Hong, H.; Senior, J.; Tong, W. Biomarkers for drug-induced liver injury. Expert Rev. Gastroenterol. Hepatol. 2014, 4, 225-234
23. Senior, J.R. New biomarker for drug induced liver injury: Are they really better? what do they diagnose? Liver Int. 2014, 34, 325-327.
24. Lewis, J.H. The art and science of diagnosing and managing drug-induced liver injury in 2015 and beyond. Clin. Gastroenterol. Hepatol. 2015, 13, 2173-2189.
25. McGill, M.R.; Jaeschke, H. MicroRNAs as signaling mediators and biomarkers of drug-and chemical-induced liver injury. J. Clin. Med. 2015, 4, 1063-1078.
26. Zheng, J.; Ji, C.; Lu, X.; Tong, W.; Fan, X.; Gao, Y. Integrated expression profiles of mRNA and microRNA in the liver of Fructus Meliae Toosendan water extract injured mice. Front. Pharmacol. 2015, 6, 236.
27. Enache, L.S.; Enache, E.L.; Ramière, C.; Diaz, O.; Bancu, L.; Sin, A.; André, P. Circulating RNA molecules as biomarkers in liver disease. Int. J. Mol. Sci. 2014, 15, 17644-17666.
28. Li, L.M.; Wang, D.; Zen, K. Micro RNAs in drug-induced liver injury. Clin. Transl. Hepatol. 2014, 2, 162-169.
29. Yang, X.; Salminen, W.F.; Schnackenberg, L.K. Current and emerging biomarkers of hepatotoxicity. Curr. Biomark. Find. 2012, 20, 43-55.
30. Lewis, P.J.S.; Dear, J.; Platt, V.; Simpson, K.J.; Craig, D.G.N.; Antoine, D.J.; French, N.S.; Dhaun, N.; Webb, D.J.; Costello, E.M.; et al. Circulating microRNAs as potential markers of human drug-induced liver injury. Hepatology 2011, 54, 1767-1776.
31. Thulin, P.; Nordahl, G.; Gry, M.; Yimer, G.; Aklillu, E.; Makonnen, E.; Aderaye, G.; Lindquist, L.; Mattsson, C.M.; Ekblom, B.; et al. Keratin-18 and microRNA-122 complement alanine aminotransferase as novel safety biomarkers for drug-induced liver injury in two human cohorts. Liver Int. 2014, 34, 367-378.
32. Su, Y.W.; Chen, X.; Jiang, Z.Z.; Wang, T.; Wang, C.; Zhang, Y.; Wen, J.; Xue, M.; Zhu, D.; Zhang, Y.; et al. A panel of serum microRNAs as specific biomarkers for diagnosis of compound- and herb-induced liver injury in rats. PLoS ONE 2012, 7, e37395.
33. Sabaté, M.; Ibáñez, L.; Pérez, E.; Vidal, X.; Buti, M.; Xiol, X.; Mas, A.; Guarner, C.; Forné, M.; et al. Paracetamol in therapeutic dosages and acute liver injury: Causality assessment in a prospective case series. BMC Gastroenterol. 2011, 11, 80.
34. Gao, H.; Li, N.; Wang, J.Y.; Zhang, S.C.; Lin, G. Definitive diagnosis of hepatic sinusoidal obstruction syndrome induced by pyrrolizidine alkaloids. J. Dig. Dis. 2012, 13, 33-39.
35. Lin, G.; Wang, J.Y.; Li, N.; Li, M.; Gao, H.; Ji, Y.; Zhang, F.; Wang, H.; Zhou, Y.; Ye, Y.; et al. Hepatic sinusoidal obstruction syndrome associated with consumption of Gynura segetum. J. Hepatol. 2011, 54, 666-673.
36. Larrey, D. Hepatotoxicity of herbal remedies. J. Hepatol. 1997, 26 (Suppl 1), 47-51.
37. Larrey, D.; Faure, S. Herbal medicine hepatotoxicity: A new step with development of specific biomarkers. J. Hepatol. 2011, 54, 599-601.
38. Larrey, D.; Faure, S. Reply to: “Herbal medicine hepatotoxicity revisited”. J. Hepatol. 2012, 56, 505.
39. Larrey, D.; Vial, T.; Pauwels, A.; Castot, A.; Biour, M.; David, M.; Michel, H. Hepatitis after germander (Teucrium. chamaedrys) administration: Another instance of herbal medicine hepatotoxicity. Ann. Intern. Med. 1992, 117, 129-132.
40. Teschke, R.; Larrey, D.; Melchart, D.; Danan, G. Traditional Chinese Medicine (TCM) and herbal hepatotoxicity: RUCAM and the role of novel diagnostic biomarkers such as microRNAs. Medicines 2016, 3, 18.
41. Teschke, R.; Eickhoff, A. Herbal hepatotoxicity in traditional and modern medicine: Actual key issues and new encouraging steps. Front. Pharmacol. 2015, 6, 72.
42. Frenzel, C.; Teschke, R. Herbal hepatotoxicity: Clinical characteristics and listing compilation. Int. J. Mol. Sci. 2016, 17, 588.
43. Teschke, R.; Danan, G. Diagnosis and management of drug-induced liver injury (DILI) in patients with pre-existing liver disease. Drug Saf. 2016, 39, 729-744.
44. Teschke, R.; Danan, G. Drug-induced liver injury: Is chronic liver disease a risk factor and a clinical issue? Expert Opin. Drug Metab. Toxicol. 2017, 13, 425-438.
45. Chen, E.Y.; Baum, K.; Collins, W.; Löve, A.; Merz, M.; Olafsson, S.; Björnsson, E.S.; Lee, W.M. Hepatitis E masquerading as drug-induced liver injury. Hepatology 2012, 56, 2420-2423.
46. FDA Guidance for Industry, Drug-Induced Liver Injury: Premarketing Clinical Evaluation. Issued July 2009. Available online: http://www.fda.gov/downloads/Drugs/GuidanceComplianceRegulatoryInformation/Guidances/UCM174090.pdf (accessed on 15 February 2017)
47. Senior, J.R. Evolution of the Food and Drug Administration approach to liver safety assessment for new drugs: Current status and challenges. Drug Saf. 2014, 37 (Suppl S1), S9-S17.
48. Au, J.S.; Navarro, V.J.; Rossi, S. Review article: Drug induced liver injury—Its pathophysiology and evolving diagnostic tools. Aliment. Pharmacol. Ther. 2011, 34, 11-20.
49. Suk, K.T.; Kim, D.J. Drug-induced liver injury: Present and future. Clin. Mol. Hepatol. 2012, 18, 249-257.
50. Abboud, G.; Kaplowitz, N. Drug-induced liver injury. Drug Saf. 2007, 30, 277-294.
51. Russmann, S.; Kullak-Ublick, G.A.; Grattagliano, I. Current concepts of mechanisms in drug-induced hepatotoxicity. Curr. Med. Chem. 2009, 16, 3041-3053.
52. Kaplowitz, N. Drug-induced liver injury. Clin. Infect. Dis. 2004, 38 (Suppl S2), S44-S48.
53. Aithal, G.P.; Grove, J.I. Genome-wide association studies in drug-induced liver injury: Step change in understanding the pathogenesis. Semin. Liver Dis. 2015, 35, 421-431.
54. Chen, M.; Borlak, J.; Tong, W. High lipophilicity and high daily dose of oral medications are associated with significant risk for drug-induced liver injury. Hepatology 2013, 58, 388-396.
55. Chen, M.; Borlak, J.; Tong, W. Predicting idiosyncratic drug-induced liver injury-Some recent advances. Expert Rev. Gastroenterol. Hepatol. 2014, 8, 721-723.
56. Teschke, R.; Frenzel, C. Drug induced liver injury: Do we still need a routine liver biopsy for diagnosis today? Ann. Hepatol. 2014, 13, 121-127.
57. Chalasani, N.; Bonkovsky, H.L.; Fontana, R.; Lee, W.; Stolz, A.; Talwalkar, J.; Reddy, K.R.; Watkins, P.B.; Navarro, V.; Barnhart, H.; et al. Features and outcomes of 889 patients with drug-induced liver injury: The DILIN Prospective Study. Gastroenterology 2015, 148, 1340-1352.
58. Teschke, R.; Stutz, G.; Strohmeyer, G. Increased paracetamol-induced hepatotoxicity after chronic alcohol consumption. Biochem.Biophys. Res. Commun. 1979, 91, 368-374.
59. Yoon, E.; Babar, A.; Choudhary, M.; Kutner, M.; Pyrsopoulos, N. Acetaminophen-induced hepatotoxicity: A comprehensive update. J. Clin. Transl. Hepatol. 2016, 4, 131-142.
60. Smilkstein, M.J.; Knapp, G.L.; Kulig, K.W.; Rumack, B.H. Efficacy of oral N-acetylcysteine in the treatment of acetaminophen overdose. N. Engl. J. Med. 1988, 319, 1557-1562.
61. Mason, A.; Sallie, R. What causes fulminant hepatic failure of unknown etiology? Am. J. Clin. Pathol. 1995, 104, 491-494.
62. Shakil, A.O.; Kramer, D.; Mazariegos, G.V.; Fung, J.J.; Rakela, J. Acute liver Failure: Clinical features, outcome analysis, and applicability of prognostic criteria. Liver Transpl. 2000, 6, 163-169.
63. Larson, A.M.; Polson, J.; Fontana, R.J.; Davern, T.J.; Lalani, E.; Hynan, L.S.; Reisch, J.S.; Schiødt, F.V.; Ostapowicz, G.; Shakil, A.O.; et al. Acetaminophen-induced acute liver failure: Results of a United States multicentre, prospective study. Hepatology 2005, 42, 1364-1372.
64. Bower, W.A.; Johns, M.; Margolis, H.S.; Williams, I.T.; Bell, B. Population-based surveillance for acute liver failure. Am. J. Gastroenterol. 2007, 102, 2459-2463.
65. Bernal, W.; Auzinger, G.; Dhawan, A.; Wendon, J. Acute liver failure. Lancet 2010, 376, 190-201.
66. Reuben, A.; Koch, D.G.; Lee, W.M.; The Acute Liver Failure Study Group. Drug-induced acute liver failure: Results of a U.S. multicenter, prospective study. Hepatology 2010, 52, 2065-2076.
67. Khandelwal, N.; James, L.P.; Sanders, C.; Larson, A.M.; Lee, W.M.; The Acute Liver Failure Study Group. Unrecognized acetaminophen toxicity as a cause of indeterminate acute liver failure. Hepatology 2011, 53, 567-576.
68. Lee, W.M.; Larson, A.M.; Stravitz, R.T. AASLD Position Paper: The Management of Acute Liver Failure: Update 2011. Avalable online: https://www.aasld.org/sites/default/files/guideline_documents/alfenhanced.pdf (accessed on 21 February 2017).
69. Nakayama, N.; Oketani, M.; Kawamura, Y.; Inao, M.; Nagoshi, S.; Fujiwara, K. Algorithm to determine the outcome of patients with acute liver failure: A data-mining analysis using decision trees. J. Gastroenterol. 2012, 47, 664-677.
70. Davern, T.J.; James, L.P.; Hinson, J.A.; Polson, J.; Larson, A.M.; Fontana, R.J.; Lalani, E.; Munoz, S.; Shakil, A.O.; Lee, W.M. Measurement of serum acetaminophen-protein adducts in patients with acute liver failure. Gastroenterology 2006, 130, 687-694